Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. - Test2 - elhamkhani - TriplyDB

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

http://www.wikidata.org/entity/Q52301110

about

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas Involvement of midkine in neuroblastoma tumourigenesis The zebrafish as a model for studying neuroblastoma Focal DNA copy number changes in neuroblastoma target MYCN regulated genes Research progress of neuroblastoma related gene variations.The prenatal origins of cancer Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Mosaic zebrafish transgenesis for functional genomic analysis of candidate cooperative genes in tumor pathogenesis.A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma.Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Neuroblastoma and MYCN Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.New insights into the genetics of neuroblastoma.New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.Recent insights into the biology of neuroblastoma.Mechanisms of neuroblastoma regression Neuroblastoma models for insights into tumorigenesis and new therapies.Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.MiR-34a deficiency accelerates medulloblastoma formation in vivo.miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.Zebrafish Leucocyte tyrosine kinase controls iridophore establishment, proliferation and survival.

P2860

Q21092404-635851C2-B355-4855-9A2A-9AF37E69086F Q27026748-A89E0638-E7C3-4D9E-A0E5-C13B854EE85B Q28070309-42546F38-C63A-4E5F-B951-B81BB0862295 Q28115604-49A71CD8-FB62-4292-9521-BC8A4C6CB799 Q33566987-C7DA82EE-FF5B-43C7-BA04-14CCF1842B1B Q33697463-97F4ED5B-1444-4F8E-B5EF-0291302A64D4 Q33699808-F1C47E27-8625-4771-8B92-5E991DE1F567 Q33757079-0FF57EF4-2D8E-4880-A8AD-F0DC06909982 Q34101007-38BAFEDB-925C-4D98-84DB-BFAF53A13116 Q34438553-5B17C9AC-9277-4FE2-923E-F61C23387E1F Q35131527-BAD9D03C-EAEB-467E-8C2C-06B769218AA2 Q35283020-2824B3F0-013E-4064-BCF6-696468A09054 Q35461402-728358E3-BCF4-45D4-AEDE-DC228C530FA6 Q35804064-DBEA131C-EFB2-46A2-B298-79B3A52F81E5 Q35984126-9E730490-1909-4C6A-A5E7-08E876F3AB33 Q36378105-5A40A189-4FAC-4B18-A3E9-48C49FB38B2E Q37201479-57D37EC8-880F-4173-A71D-E403BC0C7822 Q37353087-F0541698-3F56-4750-A6D9-DEBD3763A636 Q37405597-092D89A1-89D0-48CE-990B-C519CCB2E51B Q37420196-A0010F81-EB78-452F-A44F-7C3D6A6B5A80 Q37480414-4520F8A6-2C9E-451A-9F51-DC50FAAA4D10 Q37699419-76DD21FC-F843-474A-B9F7-3B676FB20F89 Q38070334-1D71A807-EDCA-4AE8-9879-3311EDE2D30E Q38074875-78952A57-E722-449A-BFCD-495D34BE9270 Q38130615-D78F9F0E-3833-423B-A78D-C7847C02D3AD Q38240010-239D2782-5396-4C9C-9026-BF1B8092A879 Q38261519-5562F18A-8ED9-402A-8504-56696036CC5E Q38262762-80D1D0FA-3674-4595-9B1A-DF98D0D583E4 Q38540135-2447FA89-2EAC-4FC1-BA7D-2A37CE714522 Q38694036-7439BC33-1FA5-40E2-8C38-206919507A0C Q38944728-1C6EE4F5-B5C6-4BC5-B6EE-50D5EB5438DE Q38973284-B2A03275-1F95-42CE-A98E-D2650901B259 Q39062237-91ABF281-30FE-463F-A5B6-EE5D4600B504 Q39089535-5ED1DCC3-4704-4D96-8FE3-0441889F721E Q39202569-0BAB135B-9586-427E-ADB7-4E31EBC8990F Q40999620-5B3B235E-0387-464B-ABB1-414A5099912E Q41038822-733592B1-4E98-46DD-9533-0FDA804CB464 Q41738897-C0862BB8-C6C2-4A37-AC76-EBF1A895C0E1 Q41840140-9341C1F4-1B2F-4A06-89BE-4CC94E4B2B8C Q47073202-B99C02C4-19AD-41ED-80FB-3798A31E8E36

P2860

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

http://www.wikidata.org/entity/Q52301110

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

@en

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

@nl

type

label

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

@en

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

@nl

prefLabel

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

@en

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

@nl

P1433

Q52301110-FB90C905-A2F0-425A-8F53-B25AAE6C34A9

P1476

Q52301110-08C99158-1EE0-4663-BBB6-48BF2410B824

P2093

Q52301110-067761B7-4CFF-4E49-88E8-D09077A533EB

Q52301110-18FEFF96-5581-44C2-B60F-641DC6C11776

Q52301110-2694EDA4-7CB8-4EE4-B80C-186D8F52A261

Q52301110-2FE39AB2-58B2-412E-AF0F-14AAB7BF77E5

Q52301110-3F7C588C-8B85-4C7E-8DB8-AB73508C69A9

Q52301110-42C3C23C-F0F6-4D7B-9590-BD16989B91BD

Q52301110-6343A294-B7F0-40D6-94DE-0BB0CCFF7E27

Q52301110-7FA51229-9DDE-4775-B5C8-8F64D99A8E36

Q52301110-8170D4C7-1A30-483C-A68C-04ABB2E5C9D8

Q52301110-8D924BB4-AD69-4C94-B139-C98E2D0CAB3C

P2860

Q52301110-2963BED3-B56F-4B77-9CF8-6E0A7F0596E1

Q52301110-2C443FB9-E42B-490D-AC64-A3DA5D85F330

Q52301110-36F58592-3C5F-4882-A046-43322B103A6D

Q52301110-4AB79A39-6188-4C92-B5B4-386FE37BBBD7

Q52301110-5B4CA93F-72FF-4739-AF97-65BFC7E872B5

Q52301110-5C5D1721-9095-4730-93E2-842E04F40AF5

Q52301110-7351EDD6-7E09-453F-A206-C03B77379F78

Q52301110-7AA05611-4F11-4A65-930C-B5623CCA64B9

Q52301110-960EAD78-214E-4DED-8E0C-FE8BCFF411A0

Q52301110-A723DD76-A295-41B2-88BA-6933E5B94798

P304

Q52301110-A1F06666-ED93-46DA-BDED-04FD82A48562

P31

Q52301110-145F58DD-F6D6-44DF-BDF0-C6A5625D2759

P356

Q52301110-F2F783DD-FD29-4616-8C0B-B2C3B1FD20AA

P407

Q52301110-9738E71B-FB60-42B6-97FA-697E1F5F9B4E

P433

Q52301110-DA30EC49-8ECF-453E-836C-E9976DD3469D

P478

Q52301110-816963B4-BCF2-455E-B70B-59EE194D159B

P50

Q52301110-134EFE73-0D4D-4DB7-99A3-8FB5FFF20BB9

Q52301110-323F7947-D9D6-46B4-AC9F-45BCB722D0CE

Q52301110-33567672-6546-4CA5-875E-40A9C675A331

Q52301110-3F032C6F-A7BB-4548-BD40-84FFDB64D715

Q52301110-69E3E33F-099D-49CD-A063-FE682BC248EC

Q52301110-6C65DE3A-58AC-4979-B89E-FA0FA98E0F2E

Q52301110-8830E6E0-2875-4799-A8AD-DFE781C90BE8

Q52301110-8CA5027F-DAE9-4156-8C3B-171AE5469412

Q52301110-8DB59C56-2D64-4AF8-A913-F8EF6AD599D5

Q52301110-B6E3344F-34C3-4594-9A3C-1DA27A600F27

P577

Q52301110-FF2C3017-5401-4552-82E7-00A325226C7D

P5875

Q52301110-A323DF78-D584-4C28-99ED-0A045AC5AAB1

P698

Q52301110-ECA08441-0ADE-4896-96FA-0ED6BD3B0EDA

P356

SCITRANSLMED.3003967

P1433

Science Translational Medicine

P1476

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice

@en

P2093

Andrea Odersky

http://www.w3.org/2001/XMLSchema#string

Angelika Eggert

http://www.w3.org/2001/XMLSchema#string

Annette Künkele

http://www.w3.org/2001/XMLSchema#string

Annika Spruessel

http://www.w3.org/2001/XMLSchema#string

Candy Kumps

http://www.w3.org/2001/XMLSchema#string

Johannes H Schulte

http://www.w3.org/2001/XMLSchema#string

Katharina König

http://www.w3.org/2001/XMLSchema#string

Pieter Mestdagh

http://www.w3.org/2001/XMLSchema#string

Reinhard Büttner

http://www.w3.org/2001/XMLSchema#string

Roland T Ullrich

http://www.w3.org/2001/XMLSchema#string

P2860

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Identification of ALK as a major familial neuroblastoma predisposition gene

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

Somatic structural rearrangements in genetically engineered mouse mammary tumors.

P304

141ra91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3003967

http://www.w3.org/2001/XMLSchema#string

P407

P433

141

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Jo Vandesompele

Katleen De Preter

Alexander Schramm

Sampurna Chatterjee

Lukas C Heukamp

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228325083

http://www.w3.org/2001/XMLSchema#string

P698

22764207

http://www.w3.org/2001/XMLSchema#string